Emerging Company Showcase 2022

Innovative, Fundable, Early Stage Opportunities

Each company featured in the 2022 Emerging Company Showcase was nominated, reviewed and invited to present based upon their innovative science and the quality of their management team. They presented before a panel of ‘Pitch Doctors’, early stage VCs and investors, corporate VCs, strategic partners and other investors and advisors, who asked questions about their science and strategy. 

2022 Presenting Companies

	Altis Biosystems, Inc., Durham, NC: Developing RepliGut, a stem cell derived platform that recreates the human small intestine and colonic epithelium for more biologically relevant screening of compounds, disease modeling, and microbiome research.
	Avery Therapeutics, Inc., Tuscon, AZ: Developing tissue-engineered therapeutics to treat diseases and injuries to human muscle.
	BioVinc, Pasadena, CA: Developing skeletally-selective probes to advance bone research and novel bone-targeted therapeutics.
	Bioworkshop, New York, NY: Developing an AI driven 3D printed microfluidic biochip platform that will enable scientists to accurately study diseases and develop more effective treatments for them.
	Cairn Biosciences, San Francisco, CA: Developing the COMPASS discovery platform to unlock exclusive routes to novel targets and drugs by navigating uncharted, complex and dynamic disease biology.
	Calder Biosciences, Inc., Brooklyn, NY: Developing novel vaccines for respiratory syncytial virus (RSV) and Influenza.
	Dorian Therapeutics, San Carlos, CA: Developing senoblockers, a new class of therapeutics that can rejuvenate cells and tissues, and is bringing an innovative solution for age-associated diseases.
	EtiraRx, Inc., Dallas, TX: Developing ERX-41, a oral agent with cytotoxic activity against metastatic breast cancer cells.
	Evrys Bio, Doylestown, PA: Developing broad-spectrum antivirals that target special endogenous human proteins, known as sirtuins, enhancing their natural ability to fight infections by multiple types of viruses responsible for a given disease.
	Extend Biosciences, Newton, MA: Developing a novel drug delivery platform technology that improves the pharmacokinetic properties of peptides and proteins.
	HepaTx Corporation, Palo Alto, CA: Developing stem cells therapy for liver regeneration through hepatocyte infusion as an alternative to liver transplant.
	Isoprene Pharmaceuticals, Baltimore, MD: Developing oral small molecule therapeutics for triple negative breast cancer and other cancers.
	JelikaLite Corp. New York, NY: Developing a home-based therapeutic wearable, data-device feedback system for children with autism.
	Juvena Therapeutics, Redwood City, CA: Building a computationally driven protein drug discovery and development platform to decode the therapeutic potential of secreted proteins.
	Lassogen, San Diego, CA: Developing Lassotides, a new therapeutic modality that combines the benefits and overcomes the limitations of antibodies and small molecules.
	Likarda, Boston, MA: Developing cell therapies and enabling technologies to transform the way cell therapies are delivered and function.
	Marpam Pharma, Oakdale, MN: Developing a one-time treatment for the durable remission of HIV using a patient’s own T cells to express a chimeric antigen receptor (CAR).
	Mirecule, Gaithersburg, MD: Developing RNA therapies for cancer and muscular dystrophy.
	OncoTab, Inc,. Charlotte, NC: Developing Agkura™ Personal Score, a simple, non-invasive blood test offered as a supplement to mammography for women with dense breast tissue.
	Palm Therapeutics, Inc.,San Diego, CA: Developing novel depalmitoylating drugs to access previously undruggable targets in the oncology and rare disease spaces.
	Perfusion Medical, Richmond, VA: Developing PEG-20k, an IV solution for restoration of tissue perfusion by reversing metabolic cell and tissue swelling in order to address severe blood loss, or hemorrhagic shock, and related medical conditions.
	PoP Therapeutics, Huntsville, AL: Developing the EDeN platform which utilizes synthetic biology to discover bioactive molecules for development of targeted drugs for pancreatic cancer and infectious diseases.
	Proteios Technology, Inc., Issaquah, WA; Developing technologies for the rapid, parallel isolation of biologicals, including research-scale kits for recombinant protein purification, cell isolation, recombinant antibody purification, and virus purification.
	Remedium Bio, Needham, MA : Gene therapy company streamlining development by employing novel combinations of proven technologies, including a first-in-class disease-modifying osteoarthritis treatment based on a clinically proven mechanism that has demonstrated the ability to reverse the disease.
	reVision Therapeutics, Ridgewood, NJ: Developing innovative therapies for ocular and rare diseases with a lead product candidate REV-0100 being developed as a treatment for Stargardt disease.
	Riparian Pharmaceuticals, Watertown, MA: Developing therapeutics for vascular diseases such as pulmonary arterial hypertension, coronary heart disease and atherosclerosis.
	SingletO2, New York, NY: Developing a treatment for periodontal disease that harnesses the bacteria-killing capability of singlet oxygen, enabling treatment of advanced stages of the disease without surgery.
	Summit Biomedical Imaging, New York, NY: Developing fluorescent biomarkers to find and remove cancer more effectively, enabling faster and more accurate margin determination for cancer surgeries.
	Sustained Nano Systems, Stony Brook, NY: Developing patented nanotechnology that extends the time release of a wide range of biologically active molecules in a predictable manner, from weeks to months.
	Thetis Pharma, Ridgefield, CT: Developing HEALER technology – transforms anti-inflammatory resolvins into new molecules with enhanced stability and targeted properties. www.thetispharma.com
	Trevarx Biomedical, Inc., Philadelphia, PA: Developing novel radiopharmaceutical platforms, including small molecules for the imaging and treatment of tumors.
	Trove Therapeutics, Inc., Rockville, MD: Developing biolorics to treat and prevent respiratory diseases. With a lead product entering Phase 2 trial in chronic sinusitis.
	UNandUP LLC, St. Louis, MO: Developing the TheraLode platform disrupting thrombolytic therapy across all clot conditions with accurate targeted delivery, creating new drugs by conjugating off-patent thrombolytics to iron oxide nanoparticles (IONPs).
	Young Therapeutics, Philadelphia, PA: Developing a novel treatment for ischemia/reperfusion injury with a PKCe inhibitor that stops oxygen free radicals from forming and initiating cell damage.
	View the 2021 showcase presenters here.